Q2 EPS Forecast for ARS Pharmaceuticals Reduced by Analyst

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Equities researchers at Leerink Partnrs lowered their Q2 2025 EPS estimates for ARS Pharmaceuticals in a research note issued to investors on Wednesday, May 14th. Leerink Partnrs analyst R. Ruiz now forecasts that the company will earn ($0.43) per share for the quarter, down from their prior estimate of ($0.37). The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.55) per share. Leerink Partnrs also issued estimates for ARS Pharmaceuticals' Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.50) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at $0.35 EPS and FY2028 earnings at $2.25 EPS.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, hitting the consensus estimate of ($0.35). The firm had revenue of $7.97 million during the quarter, compared to analyst estimates of $7.48 million.

Other equities analysts also recently issued research reports about the company. William Blair restated an "outperform" rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Scotiabank assumed coverage on shares of ARS Pharmaceuticals in a research note on Friday, March 7th. They set a "sector outperform" rating and a $30.00 price target on the stock. Oppenheimer started coverage on shares of ARS Pharmaceuticals in a research note on Monday, February 10th. They set an "outperform" rating and a $40.00 price target on the stock. Finally, Wall Street Zen downgraded shares of ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, ARS Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $31.00.

ARS Pharmaceuticals Trading Up 3.2%

SPRY stock traded up $0.46 during mid-day trading on Monday, hitting $14.98. The stock had a trading volume of 2,307,209 shares, compared to its average volume of 1,253,814. The company has a fifty day moving average of $13.61 and a 200 day moving average of $12.87. ARS Pharmaceuticals has a 1-year low of $7.55 and a 1-year high of $18.51. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of -29.37 and a beta of 0.84.

Institutional Trading of ARS Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SPRY. Alliancebernstein L.P. grew its stake in shares of ARS Pharmaceuticals by 1.1% in the first quarter. Alliancebernstein L.P. now owns 3,922,805 shares of the company's stock worth $49,349,000 after acquiring an additional 42,071 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of ARS Pharmaceuticals by 0.7% in the first quarter. Vanguard Group Inc. now owns 3,488,293 shares of the company's stock worth $43,883,000 after acquiring an additional 23,341 shares during the last quarter. Cormorant Asset Management LP grew its stake in shares of ARS Pharmaceuticals by 220.0% in the first quarter. Cormorant Asset Management LP now owns 1,600,000 shares of the company's stock worth $20,128,000 after acquiring an additional 1,100,000 shares during the last quarter. MPM Bioimpact LLC acquired a new stake in ARS Pharmaceuticals in the 1st quarter worth $16,519,000. Finally, Alyeska Investment Group L.P. grew its position in ARS Pharmaceuticals by 903.0% in the 4th quarter. Alyeska Investment Group L.P. now owns 1,253,724 shares of the company's stock worth $13,227,000 after purchasing an additional 1,128,724 shares during the last quarter. Institutional investors and hedge funds own 68.16% of the company's stock.

Insider Buying and Selling at ARS Pharmaceuticals

In other news, insider Eric Karas sold 10,000 shares of the firm's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the sale, the insider now directly owns 7,696 shares of the company's stock, valued at approximately $107,744. This trade represents a 56.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Laura Shawver sold 49,600 shares of the firm's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $11.21, for a total value of $556,016.00. Following the completion of the sale, the director now directly owns 210,346 shares in the company, valued at approximately $2,357,978.66. This represents a 19.08% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 382,571 shares of company stock worth $5,177,904 over the last 90 days. Insiders own 33.50% of the company's stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.